前列腺素类药物降眼压疗效个体差异的影响因素分析

Analysis the factors of individual differences in drug response of prostaglandins in reducing ocular hypotension

青光眼在全球是导致不可逆性失明的首要原因,其病理损害的共同点是特征性视神经萎缩、视网膜神经节细胞的死亡和视野缺损,病理性眼压增高是其主要危险因素。目前临床主要有六大类降眼压药物,其中前列腺素类药物是新型的抗青光眼药物,广泛应用于临床,但其疗效存在个体差异。造成个体间差异的主要因素之一是基因多态性。本文对可能造成个体差异的原因进行讨论,希望能够对临床个体化的治疗提供帮助。

Glaucoma is the leading cause of irreversible blindness in the world. The common features of the pathological damage are characterized by optic atrophy,retinal ganglion cell death and visual field defect,and increased pathological intraocular pressure is the main risk factor. There are six categories of anti- glaucoma agents at present. Among them,prostaglandin analogues are new anti- glaucoma agents,which are widely used in clinical,but there are individual differences in drug response.Genepolymorphism may be one of the main reasons for individual differences. The reasons were discussed in this review,hoping to provide help for individual therapy in clinic.